Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306597 | 0.83 | GPR119 (0.44) | USP30GPR119MEN1KMT2ANPC1 | |
| SCHEMBL20322146 | 0.72 | ALDH1A1 (0.43) | GPR119NPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL20321733 | 0.72 | ALDH1A1 (0.43) | GPR119NPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL17803257 | 0.70 | GPR119 (0.46) | USP30GPR119MEN1KMT2A | |
| SCHEMBL18319317 | 0.69 | MEN1 (0.52) | USP30GPR119MEN1KMT2A | |
| SCHEMBL3842743 | 0.69 | MEN1 (0.57) | USP30GPR119MEN1KMT2A | |
| SCHEMBL21597932 | 0.68 | PIK3CD (0.51) | GPR119NPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL7037004 | 0.68 | CACNA1B (0.60) | USP30GPR119MEN1KMT2ANPC1 | |
| SCHEMBL25967727 | 0.68 | MEN1 (0.51) | USP30GPR119MEN1KMT2A | |
| SCHEMBL29965593 | 0.68 | PDE4D (0.53) | USP30GPR119DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115374-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115374-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | USP30 3006/4885GPR119 185/4885MEN1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.